Latest Cancer News
Symptoms May Do Little to Improve Early Detection of Ovarian Cancer
(02/05/2010)
Use of symptoms to trigger medical evaluation for ovarian cancer may not greatly increase early detection of ovarian cancer, and would result in a diagnosis of ovarian cancer in only 1 out of 100 women with symptoms. These results were published in the Journal of the National Cancer Institute.Lapatinib Approved for Initial Treatment of Metastatic Breast Cancer
(02/02/2010)
The U.S. Food and Drug Administration (FDA) has expanded its approval of Tykerb® (lapatinib) to include initial treatment of metastatic, postmenopausal breast cancer that is both HER2-positive and hormone receptor-positive. In this setting, Tykerb is approved for use in combination with the aromatase inhibitor drug Femara® (letrozole).Don’t Forget About Your Heart Health
(02/01/2010)
For better or worse, thoughts of cancer breeze into many women’s minds almost as easily as thoughts of Matthew McConaughey or breaking through the glass ceiling at work. Cancer just seems to have what it takes to grab headlines and capture the attention of movie stars and the general public alike. Heart disease, on the other hand, often has trouble just getting a mention in the news, and it sorely lags in the race for the greatest number of fundraising galas. |
What's New
An Official Statement from Governor Jody Rell on "Clinical Trial Initiative Month"
On August 2rd, 2009 The sixth annual Tour of the Litchfield Hills was attended by more than 1100 participants that raised about $100,000 to benefit cancer patients of the Northwest Connecticut area.
Grant Awarded for Community Education Regarding Clinical Trials
Connecticut Oncology and Hematology is proud to announce that the practice is the recipient of a grant from the Connecticut Clinical Trials Network.
On June 26th weekend in Winsted Ct., and August 16th weekend in Caanan Ct.,Connecticut Oncology-Hematology participated in the two area RELAY FOR LIFE events.
Read More »
Research at Connecticut Oncology
EFC6521
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who are Undergoing Chemotherapy
S0421
Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer
Read More »
|
Locations
New Milford Location
New Milford Hospital
Cancer Center
21 Elm St.
New Milford, CT 06776
860-350-7283
|